News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
856,210 Results
Type
Article (87111)
Company Profile (704)
Press Release (768375)
Multimedia
Podcasts (158)
Webinars (21)
Section
Business (232930)
Career Advice (4136)
Deals (39773)
Drug Delivery (132)
Drug Development (91159)
Employer Resources (200)
FDA (18231)
Job Trends (17378)
News (397079)
Policy (39870)
Tag
Academia (3002)
Academic (2)
Accelerated approval (16)
Adcomms (33)
Allergies (111)
Alliances (56978)
ALS (127)
Alzheimer's disease (1628)
Antibody-drug conjugate (ADC) (197)
Approvals (18205)
Artificial intelligence (427)
Autoimmune disease (39)
Automation (22)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (142)
Biotechnology (482)
Bladder cancer (110)
Brain cancer (45)
Breast cancer (420)
Cancer (3350)
Cardiovascular disease (272)
Career advice (3545)
Career pathing (34)
CAR-T (220)
CDC (43)
Cell therapy (606)
Cervical cancer (27)
Clinical research (74677)
Collaboration (1208)
Company closure (4)
Compensation (806)
Complete response letters (44)
COVID-19 (2925)
CRISPR (71)
C-suite (436)
Cystic fibrosis (128)
Data (3428)
Decentralized trials (2)
Denatured (57)
Depression (88)
Diabetes (395)
Diagnostics (7019)
Digital health (27)
Diversity (10)
Diversity, equity & inclusion (49)
Drug discovery (197)
Drug pricing (167)
Drug shortages (36)
Duchenne muscular dystrophy (174)
Earnings (98565)
Editorial (51)
Employer branding (25)
Employer resources (169)
Events (131859)
Executive appointments (938)
FDA (20340)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (11)
Funding (1078)
Gene editing (154)
Generative AI (42)
Gene therapy (482)
GLP-1 (975)
Government (5322)
Grass and pollen (7)
Guidances (327)
Healthcare (20927)
HIV (47)
Huntington's disease (32)
IgA nephropathy (48)
Immunology and inflammation (201)
Immuno-oncology (17)
Indications (44)
Infectious disease (3133)
Inflammatory bowel disease (172)
Inflation Reduction Act (13)
Influenza (81)
Intellectual property (147)
Interviews (813)
IPO (17912)
IRA (59)
Job creations (5194)
Job search strategy (2863)
Kidney cancer (15)
Labor market (65)
Layoffs (613)
Leadership (28)
Legal (10142)
Liver cancer (88)
Longevity (12)
Lung cancer (467)
Lymphoma (238)
Machine learning (17)
Management (65)
Manufacturing (513)
MASH (112)
Medical device (14791)
Medtech (14803)
Mergers & acquisitions (22646)
Metabolic disorders (1020)
Multiple sclerosis (108)
NASH (23)
Neurodegenerative disease (168)
Neuropsychiatric disorders (48)
Neuroscience (2462)
NextGen: Class of 2025 (7687)
Non-profit (5094)
Now hiring (53)
Obesity (514)
Opinion (300)
Ovarian cancer (109)
Pain (138)
Pancreatic cancer (139)
Parkinson's disease (209)
Partnered (27)
Patents (363)
Patient recruitment (224)
Peanut (55)
People (65916)
Pharmaceutical (143)
Pharmacy benefit managers (25)
Phase I (23034)
Phase II (32418)
Phase III (24414)
Pipeline (2309)
Policy (270)
Postmarket research (3554)
Preclinical (10401)
Press Release (72)
Prostate cancer (163)
Psychedelics (47)
Radiopharmaceuticals (279)
Rare diseases (574)
Real estate (7404)
Recruiting (76)
Regulatory (27496)
Reports (64)
Research institute (2668)
Resumes & cover letters (650)
Rett syndrome (11)
RNA editing (14)
RSV (62)
Schizophrenia (113)
Series A (179)
Series B (130)
Service/supplier (30)
Sickle cell disease (72)
Special edition (23)
Spinal muscular atrophy (168)
Sponsored (38)
Startups (4313)
State (2)
Stomach cancer (17)
Supply chain (89)
Tariffs (81)
The Weekly (99)
Vaccines (976)
Venture capital (62)
Weight loss (354)
Women's health (53)
Worklife (20)
Date
Today (100)
Last 7 days (506)
Last 30 days (2588)
Last 365 days (34004)
2025 (21749)
2024 (38139)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1278)
Alabama (73)
Alaska (7)
Arizona (288)
Arkansas (14)
Asia (50688)
Australia (8905)
California (8478)
Canada (2590)
China (784)
Colorado (362)
Connecticut (380)
Delaware (231)
Europe (116378)
Florida (1271)
Georgia (291)
Hawaii (3)
Idaho (67)
Illinois (773)
India (39)
Indiana (412)
Iowa (19)
Japan (255)
Kansas (120)
Kentucky (34)
Louisiana (20)
Maine (75)
Maryland (1177)
Massachusetts (6447)
Michigan (289)
Minnesota (523)
Mississippi (4)
Missouri (109)
Montana (32)
Nebraska (26)
Nevada (95)
New Hampshire (75)
New Jersey (2352)
New Mexico (31)
New York (2328)
North Carolina (1313)
North Dakota (10)
Northern California (3732)
Ohio (271)
Oklahoma (17)
Oregon (49)
Pennsylvania (1802)
Puerto Rico (18)
Rhode Island (42)
South America (1654)
South Carolina (42)
South Dakota (1)
Southern California (3187)
Tennessee (137)
Texas (1327)
United States (31748)
Utah (251)
Virginia (230)
Washington D.C. (81)
Washington State (734)
West Virginia (4)
Wisconsin (89)
There are 856,210 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IPO
Biotech Finally Has an IPO After Months-Long Freeze
LB Pharma will test the IPO market to seek funding for a Phase III-ready schizophrenia asset.
August 25, 2025
·
1 min read
·
Annalee Armstrong
Acquisitions
Unswayed by Cerevel Failure, AbbVie Buys Gilgamesh’s Depression Drug for $1.2B
The deal extends AbbVie’s commitment to the psychedelics space and depression, after emraclidine’s high-profile flop in schizophrenia last November.
August 25, 2025
·
3 min read
·
Annalee Armstrong
Startups
Arnatar Debuts With $52M To Advance RNA Therapies That Go Beyond Silencing
Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare disease called Alagille syndrome.
August 25, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Sona Provides Update on First-In-Human Clinical Trial
August 25, 2025
·
4 min read
Press Releases
Defence Therapeutics Announces Debenture Units Financing
August 25, 2025
·
4 min read
Press Releases
Cancer Monoclonal Antibodies Market Size to Reach USD 577.26 Billion by 2034 Driven by Rising Demand for Targeted Cancer Therapies
August 25, 2025
·
1 min read
Press Releases
CRISPR-based Gene Editing Market Size to Reach USD 24.37 Billion by 2034
August 25, 2025
·
1 min read
Press Releases
Why Orchestration, Not Integration, Is Defining the Future of Life Sciences IT
August 25, 2025
·
1 min read
Press Releases
Contextualized Data—Not Raw Inputs—is the Key to Smarter Manufacturing and AI Success
August 25, 2025
·
1 min read
Press Releases
Model Medicines Selected to Present at BARDA’s Enabling Technologies Showcase
August 25, 2025
·
1 min read
1 of 85,621
Next
